New drug for obesity reduced weight gain by 32%
Therapies that deliver hydrogen sulphide to cells could one day become the basis of new treatments for obesity and related diseases, new research has concluded.
Mounting evidence suggests that hydrogen sulphide plays an important role in the liver. Previous research shows that tiny amounts of hydrogen sulphide in the body regulate how the liver processes fat. It also impacts the function of mitochondria.
The new study is led by Jagiellonian University Medical College in Poland and the University of Exeter and published in Pharmacological Research.
In the research, mice fed a high-fat diet were injected with the compound AP39, which delivers hydrogen sulfide direct to mitochondria in cells. The research concluded that the treatment significantly slowed the rate of weight gain, reduced by 32% on average, over the 12 weeks of the study.
The team also found that treatment reduced the accumulation of fat in the liver, which can be a complication of obesity and can lead to harmful inflammation.
Exciting new treatment for obesity
AP39 was invented at University of Exeter and is now owned by its spin-out company MitoRX Therapeutics.
The study found that in the mice, treatment with AP39 reduced the activity of processes in the liver that help create certain detrimental fats in the body, build proteins that carry fat, and regulate important signals that can be harmful to the liver. It also lowered the liver’s production of new fats by preventing the activation of a key adverse metabolic pathway (mTOR/SREBP1/NF-kB).
Study co-author Matt Whiteman, Professor of Experimental Therapeutics at the University of Exeter Medical School, first began researching the role of hydrogen sulphide in the body in 2004. He first noticed that people with type 2 diabetes who were overweight had lower levels of hydrogen sulphide in their blood.
This was determined by the amount of body fat they were carrying. Higher body fat content meant lower blood sulphide levels, which in turn meant poorer sugar control and greater insulin resistance. That suggested that these adverse changes could be prevented or reversed by drug molecules that replace the lost sulphide.
Professor Whiteman said: “These early findings suggested that hydrogen sulphide could one day play a role in treating diabetes, obesity and complications arising from having too much fat in the body. Today, obesity is a growing global health challenge, and new and better treatments are desperately needed. If our findings that hydrogen sulphide-generating molecules that target mitochondria significantly slow weight gain translate to humans, we could be looking at an exciting new option for treatment. It is gratifying to translate these observations toward clinically viable and better drugs with MitoRx.”
The paper is entitled ‘Mitochondria-targeted hydrogen sulfide donor reduces fatty liver and obesity in mice fed a high fat diet by inhibiting de novo lipogenesis and inflammation via mTOR/SREBP-1 and NF-κB signaling pathways’.
Diana Spencer, Senior Digital Content Editor, DDW
